ARG 201

Drug Profile

ARG 201

Alternative Names: ARG201; Bovine type 1 collagen - arGentis

Latest Information Update: 28 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Tennessee
  • Developer arGentis Pharmaceuticals
  • Class Extracellular matrix proteins; Fibrillar collagens
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Systemic scleroderma

Most Recent Events

  • 06 Aug 2015 Phase-II development for scleroderma is ongoing
  • 17 Feb 2009 ARG 201 receives Orphan Drug Status for Systemic scleroderma in the EU
  • 01 Jul 2008 Final efficacy data from a phase II trial in Systemic scleroderma released by arGentis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top